{
  "ticker": "NUZ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02968046",
  "id": "02968046",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250710",
  "time": "0915",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250710/pdf/06lnqpsqxvmnc1.pdf",
  "summary": "- **FDA feedback confirms procedural alignment** for NUZ-001 clinical hold resolution strategy.  \n- **Two required preclinical PK studies completed ahead of schedule**; reports being finalized.  \n- **Complete Response submission to FDA expected in coming weeks**; clinical hold lift anticipated **August 2025**.  \n- **Targeted participation in HEALEY ALS Platform Trial maintained for Q4 2025**.  \n\n*Material impact: Positive regulatory progress reduces clinical trial timeline uncertainty.*",
  "usage": {
    "prompt_tokens": 1375,
    "completion_tokens": 96,
    "total_tokens": 1471,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-09T23:23:24.155253"
}